Amryt Pharma plc (AMYT)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amryt Pharma plc ("Amryt" or the "Company") (NASDAQ: AMYT). Investors who purchased Amryt securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Amryt and certain of its officers and/or directors have violated federal securities laws.
On February 28, 2022, Amryt issued a press release “announc[ing] it has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for Oleogel-S10, for the treatment of the cutaneous manifestations of Dystrophic and Junctional Epidermolysis Bullosa (EB)”. Amyrt reported that “[t]he FDA communicated that it had completed its review of the application and has determined that the application cannot be approved in its present form” and “has asked Amryt to submit additional confirmatory evidence of effectiveness for Oleogel-S10 in EB.” On this news, Amryt’s American Depositary Share (“ADS”) price fell $1.15 per ADS, or 14.15%, to close at $6.98 per ADS on February 28, 2022.
If you are aware of any facts relating to this investigation or purchased Amryt shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.